| Study | Eligibility Criteria | Trial Duration | Treatment Arms &nbsp;&nbsp;  | Adherence | Primary Endpoint |
| :---  | :---                 | :---:          | :---                         | :---      | :---             |  
| AMIGO-1 <br> (DeFronzo et al, 2005) | Adult patients with inadequately controlled <br> T2DM (HbA1c 7.1-11.0%) on metformin monotherapy (≥ 1500 mg qd) for ≥ 3 months  | 30 weeks | <img width="150"/>exenatide 10 ug bid (N=113) <br> exenatide 5 ug bid (N=110) <br> placebo (N=113) |    |  | 


